EN DE

Prince Pharmaceutical Co (6935) Fair Value & Analysis

Healthcare · TW · Market cap 1.1B TWD

PP Prince Pharmaceutical Co 6935 · TWO
Price31.35 TWD
Fair Value49.48 TWD
Upside+57.8%
Quality60/100
Watch Prince Pharmaceutical Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 9.1% net margin
Low debt · generates free cash flow
1.69% dividend yield
Ranks above peers (12/14)
Moderate moat 48/100
Evidence: High Range 32.30 TWD – 62.82 TWD Share as image

Fair value as of: Jul 23, 2026

From 26 valuation models · updated 18 days ago

Share price +3.5% over the past month.

A solid business, screening 58% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (32.30 TWD). The market is more pessimistic than our downside scenario.
  • Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (32.30 TWD to 62.82 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (3 years)

65.50 TWD 18.68 TWD Fair Value 49.48 TWD Mar 2023 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

40‑month range 18.68 TWD – 65.50 TWD · fair‑value band 32.30 TWD – 62.82 TWD · the 31.35 TWD price screens below the 49.48 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Prince Pharmaceutical Co (6935) currently trades at 31.35 TWD, while our model-based Fair Value estimate is 49.48 TWD, implying the stock looks roughly 57.8% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Prince Pharmaceutical Co generated revenue of 1.1B TWD at a net margin of 9.1%. Revenue grew 73.7% year over year. It earns a return on equity of 12.3%. Net debt stands at 145M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 32.30 TWD (bear case) to 62.82 TWD (bull case); at 31.35 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 18% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 58%, 6935 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 22.11 TWD 39.80 TWD 67.60 TWD 80
Residual Income 19.16 TWD 21.39 TWD 34.63 TWD 76
Rev-Margin DCF 29.11 TWD 55.07 TWD 109.25 TWD 74
All 26 models by family
DCF Models
FCF DCF 23.75 TWD 35.67 TWD 71.29 TWD 38
Owner Earnings 45.21 TWD 96.05 TWD 190.37 TWD 31
5Y Revenue Exit 26.10 TWD 47.90 TWD 93.62 TWD 39
5Y EBITDA Exit 37.19 TWD 70.29 TWD 135.30 TWD 41
5Y P/E Exit 32.81 TWD 77.60 TWD 138.88 TWD 38
10Y Revenue Exit 24.42 TWD 57.94 TWD 79.88 TWD 36
10Y EBITDA Exit 32.84 TWD 79.72 TWD 162.73 TWD 37
10Y P/E Exit 29.93 TWD 71.13 TWD 139.28 TWD 35
Earnings-Based
Graham-Dodd 17.51 TWD 122.10 TWD 171.35 TWD 54
Lynch FV 61.93 TWD 88.47 TWD 115.01 TWD 50
PEG = 1.0 61.93 TWD 88.47 TWD 115.01 TWD 46
EPV 19.16 TWD 22.07 TWD 24.50 TWD 59
Dividend Discount
Gordon GGM 1.90 TWD 3.42 TWD 4.71 TWD 70
DDM Multi-Stage 1.90 TWD 3.13 TWD 3.66 TWD 61
Multiples
P/E Multiple 38.62 TWD 51.49 TWD 64.37 TWD 63
P/S Multiple 32.83 TWD 43.77 TWD 54.71 TWD 58
P/B Multiple 32.83 TWD 43.77 TWD 54.71 TWD 55
EV/EBIT 37.83 TWD 51.17 TWD 64.51 TWD 53
EV/EBITDA 42.78 TWD 57.76 TWD 72.75 TWD 54
EV/Revenue 24.79 TWD 36.35 TWD 47.91 TWD 43
Asset-Based
NCAV (Graham) 11.21 TWD 15.02 TWD 22.42 TWD 50
Growth DCF
Growth DCF 22.11 TWD 39.80 TWD 67.60 TWD 80
Rev-Margin DCF 29.11 TWD 55.07 TWD 109.25 TWD 74
Economic Profit
Residual Income 19.16 TWD 21.39 TWD 34.63 TWD 76
ROIC Compounder 19.16 TWD 22.07 TWD 27.61 TWD 72
Growth Earnings
Growth-Adj P/E 80.06 TWD 114.37 TWD 148.69 TWD 68

Widest divergence: Growth Earnings (114.37 TWD) versus Dividend Discount (3.13 TWD). Highest evidence: Growth DCF (80).

Notify me when 6935 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.1B TWD
Revenue growth (YoY) +73.7%
Net margin 9.1%
Return on equity 12.3%
Free cash flow 71.3M TWD FY2025
P/E ratio 11.7
More key figures
Operating margin 13.9%
EPS (TTM) 2.61 TWD
Dividend yield 1.7%
Net debt 145M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 60/100

Of which business quality 58 · Market factors (momentum, volatility) 56

Profitability 43
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 45
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 78
Disciplined investing over empire-building
Low Volatility 61
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 60
Distance to the 52-week high (market factor)
Net Issuance 50
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally.

Full company description

Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yúnlín, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Prince Pharmaceutical Co reported revenue of 1.1B TWD in FY2025 versus 441M TWD in FY2021, a compound +24.4%/yr. Reported net income was 96.3M TWD in FY2025.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
1.1B TWD
Latest YoY
+53.1%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.0%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+29.0%
Avg. growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+27.2%
Revenue +24.4%/yr
FY21 441M TWD
FY22 713M TWD
FY23 753M TWD
FY24 690M TWD
FY25 1.1B TWD
Net income
FY21 −8.3M TWD
FY22 51.6M TWD
FY23 15.3M TWD
FY24 −53.5M TWD
FY25 96.3M TWD

Watch 6935: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prince Pharmaceutical Co · Fair Value
49.48 TWD +58%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Prince Pharmaceutical Co Fair Value". https://www.fairvalue-calculator.com/stock/6935

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 60 · Above median
Fair Value upside +58% · Top 25%
Return on equity (TTM) 12% · Above median
Return on assets 5% · Above median
Net margin (TTM) 9% · Above median
Operating margin (TTM) 14% · Above median
Revenue growth 74% · Top 25%
Dividend yield (TTM) 1.7% · Below median
Debt / equity 0.28× · Higher than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 10.8× · Cheaper than 75% of peers
P/B 1.26× · Cheaper than median
P/S (TTM) 1.00× · Cheaper than median
P/FCF 0.5× · Cheaper than 75% of peers
EV/EBITDA 7.0× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 6
FUTURE 100 · sector 20
PAST 49 · sector 24
HEALTH 86 · sector 97
DIVIDEND 34 · sector 34

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.19 ¥25.94 -51%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,933 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹7,316 ₹1,943 -73%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,763 ₹1,329 -72%
PharmaEssentia Corporation 6446 1,285 TWD 221.01 TWD -83%
Cipla Limited CIPLA ₹1,439 ₹1,001 -30%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,151 ₹703.32 -39%
Lupin Limited LUPIN ₹2,443 ₹2,477 +1%
Mankind Pharma Limited MANKIND ₹2,484 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,211 ₹874.79 -28%

Compare Prince Pharmaceutical Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Prince Pharmaceutical Co (6935) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 49.48 TWD versus a price of 31.35 TWD, about +58% (undervalued).
What is the fair value of 6935?
Our model-based fair value for Prince Pharmaceutical Co is 49.48 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 31.35 TWD.
What is the quality score of 6935?
Prince Pharmaceutical Co has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Prince Pharmaceutical Co (6935)?
Prince Pharmaceutical Co reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 6935?
The net profit margin of Prince Pharmaceutical Co is about 9.1%, meaning it keeps roughly 9.1% of revenue as net income. Based on the latest reported figures.
Does Prince Pharmaceutical Co pay a dividend?
Prince Pharmaceutical Co currently shows a dividend yield of about 1.69% relative to its recent price (as of Jul 23, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Prince Pharmaceutical Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.